Table 1.
The oncologic outcomes of LDR brachytherapy
| Number of patients | Procedure | Definition | Median follow-up | Outcomes | |
|---|---|---|---|---|---|
| Stone et al3 (2010) | 584 | LDR ± EBRT | Phoenix | 7.1 yr | 7-yr bFFF Low: 92% Int: 84% High: 70% |
| Zelefsky et al4 (2012) | 1466 | LDR or HDR ± EBRT | Phoenix | 49 mo | 5-yr PSA-RFS Low: 98% Int: 95% High: 80% |
| Yorozu et al5 (2015) | 1313 | LDR ± EBRT | Phoenix | 67 mo | 7-yr bFFF Low: 98% Int: 93% High: 81% |
| Katayama et al6 (2019) | 2316 | LDR ± EBRT | Phoenix | 60 mo | 5-yr bFFF Low: 95% Int: 93% High: 91% |
| Tanaka et al7 (2022) | 944 | LDR ± EBRT | Phoenix | 91 mo | 7-yr BCR-free rate Low: 95% Int: 95% High: 91% |
| Tsumura et al8 (2022) | 204 | LDR (n = 102) vs. LDR + EBRT (n = 102) | Phoenix | 95 mo | 8-yr BCR-free rate LDR vs. LDR + EBRT Int: 93% vs. 88% P = 0.047 |
BCR, biochemical recurrence; bFFF: biochemical freedom from failure; EBRT, external beam radiation therapy; HDR, high-dose rate brachytherapy; High, high-risk; Int., intermediate-risk; Low, Low-risk; LDR, low-dose-rate brachytherapy; PSA-RFS, prostate specific antigen relapse-free survival.